The issue of CBD and THC testing often arises among wellness hemp users, especially when it comes to driving, traveling, or simply purchasing compliant products in France and Europe. Many believe that a “new European framework” has established a single rule for all EU countries. In reality, the situation is more nuanced: Europe sets benchmarks, encourages harmonization on certain points, but still leaves considerable room for national legislation, particularly regarding roadside checks and penalties.
For adults who consume CBD , it is therefore essential to distinguish between three issues: the status of hemp in relation to cannabis, the rules for THC testing while driving, and health precautions regarding CBD in food. Here is what the most recent European framework says in concrete terms, with a clear overview of what has changed, what has not, and what you need to know before buying or consuming it.
A European framework, but not a single rule for screening
The first key point to remember is simple: the “new European framework” does not create a single rule for CBD/THC testing while driving that is automatically valid throughout the European Union. Approaches remain national. Each member state retains its own procedures, thresholds, penalties, and sometimes its own way of interpreting the presence of THC in the body.
However, the European Union encourages greater harmonization, particularly regarding road safety and research on driving under the influence. In other words, Brussels does not replace national laws, but rather promotes better comparison of practices, the production of shared data, and improved enforcement tools. This is a key point in understanding why rules can still vary from one country to another, even within an increasingly structured European context.
For French or European consumers, this means that a legal CBD product doesn't automatically offer the same peace of mind everywhere when it comes to roadside checks. The product's commercial status and the risk of being detected are two different things. It is precisely this distinction that explains many misunderstandings surrounding CBD, THC, and drug testing.
Roadside screening: the rise of saliva tests in Europe
Roadside saliva tests are now used in 15 European countries. This increase demonstrates that roadside checks are becoming more standardized, even if the legal implications remain at the national level. In many countries, the system involves two steps: a saliva test specifically targeting THC, followed by a behavioral assessment or further verification.
This point is important for CBD consumers. A roadside saliva test doesn't aim to "validate" that you've consumed a legal product; it primarily seeks to detect markers related to THC. Even if you're using a compliant hemp product, caution remains essential, as the presence of trace amounts of THC can cause problems depending on the product consumed, the timing of consumption, and local regulations.
In practice, this means that you should never confuse “legal CBD” with “absolutely no risk in a drug test.” Reputable products, lab-tested and compliant with regulations, reduce uncertainty about their composition. But from the perspective of roadside checks, the key element remains the detection of THC, not simply the product's label.
THC thresholds may change with new data
EUDA indicates that “emerging signs” from studies on consumption patterns could lead to a revision of the maximum blood THC levels. Currently, these levels are often set around 5 ng/ml in discussions or reference frameworks, but they are not fixed. New consumption habits, product forms, and usage profiles are prompting authorities to re-examine the appropriateness of certain levels.
This potential development is of direct interest to anyone following CBD and THC news. The hemp market has diversified considerably since 2016, with oils, flowers, resins, extracts, and new-generation cannabinoids. However, consumption patterns influence how these compounds are absorbed, metabolized, and potentially detected. Regulators are therefore seeking to better adapt detection tools to current realities.
However, caution is still advised: discussing a possible revision of the thresholds does not mean that a more lenient or stricter rule already applies everywhere. At this stage, the main message is that the situation is evolving. For consumers, the best approach remains to prioritize clearly analyzed products, maintain a safety margin before driving, and follow the specific rules of the country they are in.
Europe clearly distinguishes between industrial hemp and cannabis
From a legal standpoint, the European Union clearly distinguishes between industrial hemp and cannabis intended for the production of narcotics. Hemp is defined as having a very low THC content and, when it complies with the rules of the Common Agricultural Policy, is not intended for the production of narcotics. This distinction is fundamental for the entire CBD sector in Europe.
In practical terms, this separation allows for the regulation of the cultivation, processing, and marketing of hemp products within a specific legal framework. This does not mean that all derivative products are automatically authorized for all uses, but it confirms that compliant hemp is not legally treated as illicit cannabis in its agricultural and economic aspects.
For buyers, this is a crucial indicator. When a product is made from legal hemp, sourced from reputable supply chains, and accompanied by testing, it operates within a regulated framework that has nothing to do with the illicit market. However, this agricultural and commercial distinction does not eliminate all issues related to drug testing, as roadside checks look for traces of THC, not just the product's legal origin.
European regulations governing THC in hemp
The European Commission today links the control of THC in hemp to several legal bases of the CAP, in particular Regulation (EU) 2021/2115 and Delegated Regulation (EU) 2022/126. These texts structure the conditions under which hemp production can be recognised within the European agricultural framework, with a logic of conformity, traceability and control.
A delegated act from 2026, Delegated Regulation (EU) 2026/177, further clarified the eligibility conditions for payments for hemp production. In particular, it maintains the requirement for certified seeds and verification of THC content. This point is crucial, as it demonstrates that Europe is not content with an abstract definition of hemp; it is also imposing concrete control mechanisms upstream in the supply chain.
The European Commission also specifies that maximum levels of Δ9-THC in hemp seeds and derived products are regulated by Regulation (EU) 2023/915. For the end consumer, this reinforces the incentive to buy from transparent sellers who can document the origin of raw materials and laboratory analyses. In an increasingly professional market, documentary compliance is becoming almost as important as the product itself.
CBD food: EFSA calls for caution
From a health perspective, the EFSA published a provisional safety value for CBD in food on February 9, 2026: 0.0275 mg/kg/day, or approximately 2 mg per day for a 70 kg adult. This figure has made a strong impression, as it serves as a reminder that the regulatory treatment of CBD in food remains cautious at the European level.
However, EFSA highlights persistent gaps in the available data on CBD. In short, the authorities believe that robust evidence is still lacking to draw definitive conclusions about the long-term safety of certain forms of consumption, particularly regarding dosage, duration of use, and user profiles. This caution does not mean that CBD is banned in principle, but rather that it remains under close scientific scrutiny.
For consumers, the message is twofold. On the one hand, it's important to avoid overly simplistic claims like "100% natural, therefore automatically free of regulatory issues." On the other hand, it's preferable to choose products that are clearly formulated, tested, and offered with transparent information. In a rapidly evolving sector, analytical quality and clear dosage information are far more reliable indicators than exaggerated marketing promises.
CBD as a novel food and the limits of scientific evidence
The European Commission considers CBD a “novel food” when it meets the conditions set out in European legislation on novel foods. This means that, for food use, CBD is not treated as an ordinary ingredient. It falls under a specific framework that imposes particular evaluation and requirements before it can be placed on the market in compliance with regulations.
EUDA also points out that, since 2016, CBD products have been widely promoted, while for most uses, scientific evidence remains limited. This is a useful reminder in a market where the supply has multiplied. Between oils, gummies, drinks, extracts, and enriched formulations, commercial enthusiasm has often outpaced comprehensive scientific validation.
For an informed buyer, this doesn't mean avoiding all CBD products. Rather, it means adopting an informed approach: checking analyses, understanding the composition, avoiding misleading health claims, and favoring reputable companies. The new European framework doesn't close the door to CBD, but it clearly emphasizes rigor, safety, and consumer information.
New cannabinoids, public health, and increased vigilance
The European Cannabis Report 2026 notes that some synthetic or “new” cannabinoid products are often made from CBD extracted from low-THC cannabis, i.e., hemp. This development illustrates the rapid transformation of the market. We are no longer simply dealing with the classic opposition between CBD and THC: we are seeing the emergence of a whole ecosystem of molecules, conversions, and hybrid products that complicate regulatory interpretation.
At the same time, the public health challenges remain very real. In 2024, individuals entering specialized treatment for cannabis-related problems accounted for 33% of all reported treatment requests in the EU, Norway, and Turkey. The report also indicates that in 2025, of the 63 cities with available data, 33% reported an annual increase in THC-COOH in wastewater, while 44% reported a decrease. These figures paint a contrasting picture, but one that is still being closely monitored.
EUDA also estimates that more than half of EU countries still consider imprisonment a possible penalty for possession of cannabis for personal use, even though the general trend since 2000 has been towards less incarceration. This underscores a crucial reality: the European environment is evolving, but it is not uniformly liberal. For consumers of hemp products, legal caution therefore remains essential, especially when traveling across borders.
Ultimately, the current European framework focuses primarily on three areas: road safety, the distinction between hemp and cannabis, and health precautions regarding CBD in food. While there is currently no single rule for CBD/THC testing across the entire Union, roadside checks are being stepped up, detection tools are becoming more widespread, and discussions on THC thresholds continue to evolve.
For a more worry-free experience, the best approach is to choose products made from legal hemp, lab-tested, clearly labeled, and sold by transparent professionals. And above all, when it comes to driving, it's best to remain very cautious: a product that is commercially compliant doesn't automatically eliminate the risk of a drug test. In the world of CBD, information and quality truly make all the difference.
